ProCE Banner Activity

Psychiatry Research Review

Text Module

A faculty expert discusses advances in research for agitation in dementia, insomnia, antipsychotics in schizophrenia, and SSRI use in COVID-19 and the clinical implications, strengths, limitations, and salient conclusions of each study.

Released: December 22, 2021

Expiration: December 21, 2022

No longer available for credit.

Share

Faculty

Sanjay Gupta

Sanjay Gupta, MD

Clinical Professor
Department of Psychiatry
SUNY at Buffalo Jacobs School of Medicine
Chief Medical Officer
BryLin Behavioral Health System
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Learning Objectives

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Sanjay Gupta, MD

Clinical Professor
Department of Psychiatry
SUNY at Buffalo Jacobs School of Medicine
Chief Medical Officer
BryLin Behavioral Health System
Buffalo, New York

Sanjay Gupta, MD, has disclosed that he has received speaker fees from AbbVie, Alkermes, Intracellular Therapies, Janssen, Neurocrine, Otsuka, and Sunovion and consulting fees from Intracellular Therapies.

Staff Disclosure

Staff

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.